Jim Heighway

Medicine · Health Sciences

34h-index4.1kcitations89works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(17), Cancer-related Molecular Pathways(17), RNA modifications and cancer(14), DNA Repair Mechanisms(10), Cancer Genomics and Diagnostics(8)

Publications89 total

Nanospan, an alternatively spliced isoform of sarcospan, localizes to the sarcoplasmic reticulum in skeletal muscle and is absent in limb girdle muscular dystrophy 2F
Skeletal Muscle·2017· 4 citedOpen Access
A strategyfortherapid isolation ofnew PCR basedDNA polymorphisms
2017
Molecular Biology of Lung Cancer as the Basis for Targeted Therapy
Lung Cancer·2016
FOLFOX4 With Cetuximab vs. UFOX With Cetuximab as First-Line Therapy in Metastatic Colorectal Cancer: The Randomized Phase II FUTURE Study
Clinical Colorectal Cancer·2013· 23 citedOpen Access
Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer
Lung Cancer·2013· 7 cited
Lung: Small cell cancer
Atlas of Genetics and Cytogenetics in Oncology and Haematology·2011· 2 citedOpen Access
LPHN2 (latrophilin 2)
Atlas of Genetics and Cytogenetics in Oncology and Haematology·2011Open Access
SERPINB5 (serpin peptidase inhibitor, clade B (ovalbumin), member 5)
Atlas of Genetics and Cytogenetics in Oncology and Haematology·2011· 1 citedOpen Access
Lung tumors: an overview
Atlas of Genetics and Cytogenetics in Oncology and Haematology·2011· 1 citedOpen Access
Lung: Non-small cell carcinoma
Atlas of Genetics and Cytogenetics in Oncology and Haematology·2011· 3 citedOpen Access
Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer
The Oncologist·2010· 21 citedOpen Access
Aurora Kinases as Anticancer Drug Targets
Clinical Cancer Research·2008· 383 cited
ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology·2007· 104 citedOpen Access
Molecular Biology of Lung Cancer as the Basis for Targeted Therapy
Translational medicine series·2007· 1 cited
Origin and prognostic value of circulating KRAS mutations in lung cancer patients
Cancer Letters·2007· 93 cited
Cyclin D1 in non-small cell lung cancer: A key driver of malignant transformation
Lung Cancer·2006· 238 cited
Glutathione-S-Transferase P1 Isoenzyme Polymorphisms, Platinum-Based Chemotherapy, and Non-small Cell Lung Cancer
Journal of Thoracic Oncology·2006· 37 citedOpen Access
Glutathione-S-Transferase P1 Isoenzyme Polymorphisms, Platinum-Based Chemotherapy, and Non-small Cell Lung Cancer
Journal of Thoracic Oncology·2006· 61 citedOpen Access
Over-expression of Microspan, a novel component of the sarcoplasmic reticulum, causes severe muscle pathology with triad abnormalities
Journal of Muscle Research and Cell Motility·2006· 16 cited
Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum‐based chemotherapy in advanced nonsmall cell lung cancer
Cancer·2006· 49 cited
page 1 of 5Next →

Frequent Co-authors

Daniel Betticher(15), Mathias Gugger(8), Daniel Ratschiller(8), Paul R. Hoban(7), Андреас Каппелер(6), N. Thatcher(5), Oliver Gautschi(5), Silvia Vonlanthen(5), Markus Borner(5), Mauro Santibanez‐Koref(5), DC Betticher(4), Shirley L. Smith(4), John K. Field(4), Tim Ward(4), Julie Morris(4), Gavin White(4), H. J. Altermatt(3), H. J. Altermatt(3), P S Hasleton(3), Naomi L. Bowers(3)